These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30843778)

  • 1. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010-2016): concomitant analysis of oritavancin in vitro activity.
    Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Chemother; 2018 Sep; 30(5):280-289. PubMed ID: 30843778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.
    Pfaller MA; Sader HS; Flamm RK; Castanheira M; Mendes RE
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):199-204. PubMed ID: 29567128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.
    Pfaller MA; Jones RN; Doern GV; Sader HS; Kugler KC; Beach ML
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):283-97. PubMed ID: 10212756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).
    Pfaller MA; Sader HS; Castanheira M; Flamm RK; Mendes RE
    J Antimicrob Chemother; 2018 Apr; 73(4):916-922. PubMed ID: 29294031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oritavancin
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Carvalhaes CG
    J Chemother; 2023 Dec; 35(8):689-699. PubMed ID: 37746914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities.
    Wisplinghoff H; Seifert H; Tallent SM; Bischoff T; Wenzel RP; Edmond MB
    Pediatr Infect Dis J; 2003 Aug; 22(8):686-91. PubMed ID: 12913767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
    Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
    Biedenbach DJ; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
    Carvalhaes CG; Sader HS; Streit JM; Castanheira M; Mendes RE
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0166721. PubMed ID: 34807761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.
    Mendes RE; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1579-81. PubMed ID: 24505091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.
    Mendes RE; Castanheira M; Farrell DJ; Flamm RK; Sader HS; Jones RN
    J Antimicrob Chemother; 2016 Dec; 71(12):3453-3458. PubMed ID: 27609052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).
    Pfaller MA; Flamm RK; Duncan LR; Shortridge D; Smart JI; Hamed KA; Mendes RE; Sader HS
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):304-313. PubMed ID: 30808530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.
    Wisplinghoff H; Bischoff T; Tallent SM; Seifert H; Wenzel RP; Edmond MB
    Clin Infect Dis; 2004 Aug; 39(3):309-17. PubMed ID: 15306996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients.
    Sader HS; Fritsche TR; Jones RN
    J Chemother; 2008 Oct; 20(5):570-6. PubMed ID: 19028618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
    Sader HS; Farrell DJ; Jones RN
    J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020).
    Sader HS; Castanheira M; Huband MD; Shortridge D; Carvalhaes CG; Mendes RM
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):867-873. PubMed ID: 35355158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.
    Pfaller MA; Sader HS; Flamm RK; Castanheira M; Smart JI; Mendes RE
    Microb Drug Resist; 2017 Sep; 23(6):718-726. PubMed ID: 28727951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.